Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Pfizer to license COVID-19 antiviral

by Michael McCoy
November 21, 2021 | A version of this story appeared in Volume 99, Issue 42

 

Pfizer will license its COVID-19 antiviral, PF-07321332, to the Medicines Patent Pool (MPP), which will make the drug available to generic-drug makers in low- and middle-income countries, assuming it is approved. Merck & Co. struck a similar deal with MPP in October for its investigational antiviral, molnupiravir. Pfizer says lower-income countries will pay a not-for-profit price.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.